Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07775482 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07775482 · ClinicalTrials.gov record · last posted 2026-08-20

Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial

Study acronym: FiPAKI
StatusNot Yet Recruiting
PhaseNot applicable
Started2027-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI). This study will explore whether finerenone can mitigate the risk of transitioning to chronic kidney disease following a moderate to severe AKI. Participants will be randomly assigned to receive either finerenone or a placebo, once daily for up to 45 days, in addition to their standard care. The study will monitor for side effects such as serum potassium levels and blood pressure, and will assess whether the drug helps prevent AKI from progressing to chronic kidney disease. This is a pilot feasibility study involving approximately 72 participants across 4-5 sites in Quebec and Ontario.
Trial Details
NCT Number NCT07775482
Lead Sponsor Jean-Maxime Côté
Conditions Acute Kidney Injury, Renal Insufficiency,Chronic, Kidney Diseases
Enrollment 72 participants
Start Date 2027-01
Primary Completion 2029-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-20